LITTLE KNOWN FACTS ABOUT MAM-2201.

It is concluded that EAM-2201 has the likely to induce in vivo pharmacokinetic drug interactions when co-administered with substrates of CYP2C8, CYP3A4 and UGT1A3, and is evaluated in pooled human liver microsomes.The strategy along with the parameterization is tested for many floor and bulk difficulties. Specifically we current calculations in the